Upcoming Allied Market Research
Insulin Biosimilars Market

Insulin Biosimilars Market

Size, Share, Competitive Landscape and Trend Analysis Report by Product Type (Rapid-acting biosimilar, Long-acting biosimilar, Premixed biosimilar), by Indicative (Type I Diabetes, Type II Diabetes) and by End User (Hospitals, Ambulatory Surgical Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A14003
Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.


Biosimilars are biological products that have active properties that are similar to those of a previously licensed drug and have no clinically relevant differences in terms of safety and effectiveness. Insulin biosimilars are biosimilars that are indistinguishable from the reference insulin product and have already been approved or licensed by the FDA. Biosimilars are made using similar manufacturing procedures to those used by the patented product, but not necessarily identical to those used by the patent holder.

Patents for insulin formulations were about to expire or had already expired due to an increase in insulin manufacturers from both developed and developing countries. This necessitated the need for biosimilar insulin approvals in highly regulated markets.

COVID-19 Impact analysis

  • COVID-19 disease has infected millions of individuals around the world at the beginning of 2021. Most sectors have been severely impacted, except medical supplies and life support products, and the human insulin sectors have been severely hit. COVID-19 is anticipated to increase the number of diabetes cases, and as the pathophysiology of COVID-19-induced diabetes is more recognized, there will be more patients in need of targeted therapies.
  • COVID-19 may induce T1D by destroying insulin-producing cells in the pancreas, either directly or as a result of inflammation caused by the immune system combating the virus. The COVID-19 virus may thrive in high-blood-glucose environments, which could lead to T2D. This is projected to lead to the development of insulin biosimilars.

Top Impacting Factors
The market is being propelled by an increase in elderly population, high prevalence of Type 1, Type 2, and gestational diabetes, and surge in need for fast-acting insulin analogs.
Government agencies' increased investment in R&D activities related to insulin biosimilars boosts the market growth.
Furthermore, the low cost of biosimilar insulin for diabetes treatment, combined with its efficacy, is expected to open up new growth opportunities for the global insulin biosimilars market.
Several firms are focusing on the development of medical devices that make biosimilar insulin delivery less painful and self-delivered. The global insulin biosimilars market is predicted to grow as a result of this aspect.
Furthermore, insulin manufacturing companies are expected to lose their patents in the near future, providing abundant development prospects for the global insulin biosimilars market.
However, generic manufacturers are likely to take a smaller chunk of the amount owing to their local presence which would restrain the growth of the market.

Market Trends
New product launches to flourish the market

  • In March 2019, Eli Lilly announced that the company is introducing a lower-priced authorized generic of its originator insulin lispro brand, Humalog, into the U.S. market. Eli Lilly has indicated that the list price of its authorized generic will be 50 percent lower than the current list price of Humalog and that it will be marketed under a different subsidiary brand. This strategy has been observed in other areas of the industry, with a recent example being Gilead launching authorized generics of its hepatitis C drugs Harvoni and Epclusa at a 75 percent list price discount to the brands, under its subsidiary company Asegua Therapeutics. Like Gilead and other companies that have adopted this strategy, Eli Lilly has done so under growing political and public pressures to lower its drug prices.
  • In August 2020, Mylan N.V. and Biocon Biologics India Ltd., announced the U.S. launch of Semglee™ (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of diabetic ketoacidosis. Semglee, which received final approval from the U.S. Food and Drug Administration (FDA), has an identical amino acid sequence to Sanofi's Lantus® and is approved for the same indications.

Key Benefits of the Report

  • This study presents the analytical depiction of the Insulin Biosimilars along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Insulin Biosimilars market share.
  • The current market is quantitatively analyzed to highlight the Insulin Biosimilars market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed Insulin Biosimilars market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Insulin Biosimilars Report

  • Who are the leading market players active in the Insulin Biosimilars market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections would help in taking further strategic steps?
  • What is "Insulin Biosimilars "?
  • What is "Insulin Biosimilars " Market prediction in the future?
  • Who are the leading global players in the "Insulin Biosimilars " Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Insulin Biosimilars " Market report?

Insulin Biosimilars Market Report Highlights

Aspects Details
By Product Type
  • Rapid-acting biosimilar
  • Long-acting biosimilar
  • Premixed biosimilar
By Indicative
  • Type I Diabetes
  • Type II Diabetes
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Sanofi S.A, Merck & Co., Sandoz, NOVO Nordisk A/S, Fresenius Kabi, Boehringer Ingelheim, Eli Lilly & Co., Pfizer Inc, Mylan N.V., others., Biocon

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Purchase Options

Call or Email Us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Insulin Biosimilars Market

Start reading.
This Report and over 71,323+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,870
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Related Reports

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of the scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time for readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of the scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save the time of readers